Lifecore Biomedical (NASDAQ:LFCR) vs. Evolus (NASDAQ:EOLS) Head to Head Comparison

Evolus (NASDAQ:EOLS) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, risk, earnings, valuation, institutional ownership and dividends.

Insider and Institutional Ownership

90.7% of Evolus shares are owned by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are owned by institutional investors. 5.0% of Evolus shares are owned by insiders. Comparatively, 32.7% of Lifecore Biomedical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Evolus has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Comparatively, Lifecore Biomedical has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.

Profitability

This table compares Evolus and Lifecore Biomedical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evolus	-10.85%	N/A	-13.00%
Lifecore Biomedical	-29.93%	N/A	-16.16%

Analyst Recommendations

This is a summary of current recommendations and price targets for Evolus and Lifecore Biomedical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolus	1	1	4	0	2.50
Lifecore Biomedical	1	4	0	0	1.80

Evolus currently has a consensus price target of $14.50, indicating a potential upside of 100.75%. Lifecore Biomedical has a consensus price target of $6.50, indicating a potential upside of 1.33%. Given Evolus’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Evolus is more favorable than Lifecore Biomedical.

Valuation & Earnings

This table compares Evolus and Lifecore Biomedical”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolus	$297.18 million	1.61	-$51.64 million	($0.52)	-13.89
Lifecore Biomedical	$128.87 million	1.88	-$40.50 million	($1.07)	-6.00

Lifecore Biomedical has lower revenue, but higher earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.

Summary

Evolus beats Lifecore Biomedical on 9 of the 13 factors compared between the two stocks.

About Evolus

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

About Lifecore Biomedical

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.